EN

NKCL Bio Group has won the Grand Prize in the NK cell therapy category at the ‘2022 Consumer Selected Quality Satisfaction Award’

NKCL 2022.06.30 18:25 조회 77


220630_디지틀조선_2022-소비자가-선정한-품질-만족-대상.png

텔방송출1.png

텔방송출2.png

텔방송출3.png

Dong-hwa Shin, chairman of NKCL Bio Group Inc.(NKCL Bio Group), was honored with the Grand Prize in the NK cell therapy category of the ‘2022 Consumer Selected Quality Satisfaction Award’.

 

Celebrating its 13th anniversary this year, the '2022 Consumer Quality Satisfaction Award' is an award ceremony hosted by the Digital Chosun Ilbo and sponsored by the Chosun Ilbo and Ministry of Trade, Industry and Energy. It selects the best companies trusted and loved by consumers by implementing quality development and service for customer satisfaction.

 

NKCL Bio Group has been continuously researching and developing NK cells from 2019 to the present, and with the initiation of the construction of an automated NK cell culture system, it was highly praised for leading the development of the domestic bio industry, opening the NKCL culture center in China and successfully launched an immune care products, etc.

 

NK cell therapy is a personalized solution that does not put any strain on the patient's body. It is also called the fourth anticancer drug, and it shows excellent effects on the immune response  regulation in vivo to improve the immune function of normal people.

 

In addition, NKCL Bio Group has registered a total of 15 intellectual property rights globally, including 9 registered patents and 6 applied patents for related technologies, in order to diversify business in regards to NK cell therapy. In addition, we are leading the development of NK cell, immune-based products and technologies by registering 23 trademarks, and are preparing to open a 'Global Immune Care Center' in Yeongjongdo within this year to attract foreign patients from overseas for NK cell treatment.

 

Chairman Shin Dong-hwa said, “As the immunotherapy market grows, more companies are announcing data according to clinical progress. In particular, the biggest reason NK cell therapeutics are in the spotlight is that NK cells are the best to kill cancer cells among immune cells.”

 

He added, "Based on the 'Personalized Immune Care Platform', NKCL has developed a cell culture technology platform that can mass-produce NK cells by building a GMP facility, an automated culture system that introduces AI (artificial intelligence). Based on this, NKCL will continue to develop highly active NK cell immune enhancement products and spur the development of NK cell therapeutics.”

 


Meanwhile, at the ‘2022 Consumer Selected Quality Satisfaction Award’ ceremony, SPC Group (integrated membership) has won the award for 7 consecutive years, Paris Croissant (Bakery) for 9 consecutive years, Body Friend (Healthcare) for 6 consecutive years. Shin Dong-hwa, chairman of NKCL Bio Group (NK cell therapy), was newly listed in this year.

 

 

https://www.sisunnews.co.kr/news/articleView.html?idxno=166167